Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07735819
PHASE2

Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma

Sponsor: Barbara Ann Karmanos Cancer Institute

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to evaluate Positron emission tomography/computed tomography (PET/CT) imaging with the radiotracer 1-(2-\[18F\]fluoroethyl)-l-tryptophan (\[18F\]FETrp) in patients diagnosed with a glioma. This study has 3 aims: * to assess if the \[18F\]FETrp PET/CT can outperform Magnetic Resonance Imaging (MRI) by providing a better treatment target volume in newly diagnosed Stage 4 glioma patients * better differentiate tumor progression from radiation induced MRI changes in post treatment stage 4 gliomas * by giving a drug that can inhibit a pathway to allow objective assessment of treatment effects in low grade gliomas

Official title: Tryptophan-kynurenine Pathway PET Imaging in Human Gliomas

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

61

Start Date

2026-09

Completion Date

2031-06-30

Last Updated

2026-07-30

Healthy Volunteers

No

Interventions

DRUG

Minocycline 200mg/day

Minocycline 200mg orally daily to start within 14 days of the first \[18F\]FETrp PET/CT and taken until the second \[18F\]FETrp PET/CT obtained 25-44 days after the start of the Minocycline in Arm 3

DIAGNOSTIC_TEST

[18F]FETrp PET/CT

\[18F\]FETrp PET/CT used in all three arms

Locations (1)

Karmanos Cancer Institute

Detroit, Michigan, United States